Rapid Read    •   7 min read

SpaceX Aborts Satellite Launch 11 Seconds Before Liftoff, Reschedules for Next Day

WHAT'S THE STORY?

What's Happening?

SpaceX aborted the launch of two SES O3b mPOWER internet satellites just 11 seconds before liftoff on July 21, 2025. The launch was scheduled from Cape Canaveral Space Force Station, with a Falcon 9 rocket set to carry the payload. Despite a 90-minute launch window, SpaceX decided to stand down for the day, citing no specific reason for the abort. The company announced plans to attempt the launch again on July 22, with the vehicle and payload reported to be in good condition. The O3b mPOWER constellation, operated by Luxembourg-based SES, aims to enhance global internet connectivity and is already partially operational.
AD

Why It's Important?

The aborted launch highlights the complexities and challenges of space missions, even for experienced companies like SpaceX. The O3b mPOWER satellites are crucial for expanding global internet access, particularly in remote areas. Delays in their deployment could impact SES's service expansion plans and affect customers relying on enhanced connectivity. Additionally, the incident underscores the importance of rigorous safety protocols in space operations, as last-minute aborts are often necessary to prevent potential failures. The successful deployment of these satellites is vital for SES's competitive positioning in the satellite internet market.

What's Next?

SpaceX plans to retry the launch on July 22, with a two-hour window starting at 5:12 p.m. EDT. The company will provide a live stream of the event, allowing the public to follow the proceedings. Stakeholders, including SES and its customers, will be closely monitoring the launch, as any further delays could have financial and operational implications. The successful launch and deployment of the satellites will be a significant step forward for SES's mPOWER constellation, contributing to its goal of providing comprehensive global internet coverage.

AI Generated Content

AD
More Stories You Might Enjoy